Trump administration says Medicaid will stop paying for certain child gender-transition “hormones and surgeries,” citing experimental procedures

The Trump administration announced that Medicaid will stop funding certain treatments for children related to gender transition, including hormones and surgeries, the New York Post reported Tuesday. The paper said the administration’s position is that the procedures are experimental and that taxpayers should not be paying for them through the federal-state health program.

The report described the action as a Medicaid funding change tied to coverage decisions for child patients. It framed the move as an effort to limit public spending on treatments the administration characterized as unproven in the pediatric context, while directing state Medicaid programs toward revised coverage practices.

Because Medicaid is jointly administered by the federal government and the states, a federal change typically translates into state plan amendments, policy updates, and revised reimbursement rules. The practical effect, according to the report, is that states would be expected to adjust what services they cover for eligible beneficiaries under their Medicaid authorities.

The New York Post said the administration presented the step as part of a broader effort to protect children from procedures it described as experimental. The report did not, in the material provided here, specify the document type or administrative mechanism used to make the change, such as a rulemaking effort, guidance memo, contract policy update, or enforcement directive.

The change comes amid continuing national disputes over how publicly funded health systems should handle pediatric care related to gender transition. Legal challenges and policy reversals have been common in other contexts where states have altered Medicaid coverage, and any new federal funding position can be subject to litigation or administrative review depending on how it is implemented.

Absent additional primary documentation in the provided record, further details such as effective dates, scope of services, whether the policy applies only to Medicaid coverage or also to related federal payment programs, and the status of any carve-outs or appeals processes could not be confirmed for this write-up.